 Context Therapeutics NASDAQ:CNTX Inc has designated CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 CLDN6 positive cancers, the company announced. The CLDN6 gene is differentially expressed on cancer cells but has no or very low expression in normal, healthy tissue. 